TScan Therapeutics's total assets for Q3 2024 were $348.03M, a decrease of -7.16% from the previous quarter. TCRX total liabilities were $118.94M for the fiscal quarter, a -0.59% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.